Tag Archive for: OSE Immunotherapeutics

AbbVie on Wednesday entered into a strategic partnership with OSE Immunotherapeutics to advance the French biotech’s early-stage monoclonal antibody OSE-230 as a treatment for chronic and severe inflammation.

A review of the latest executive moves in the pharma industry over the past several months.